查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
在製藥、生物科技企業的藥物研發階段的聯盟契約和條件 (2014？2020年)
市場調查報告書
商品編碼
121841

在製藥、生物科技企業的藥物研發階段的聯盟契約和條件 (2014？2020年)

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023
出版日期: | 出版商: Current Partnering | 英文 2500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球主要製藥企業及生物科技企業，在藥物研發階段的聯盟契約的締結趨勢的相關調查，契約概要和目的，支付條件，各契約、疾病、技術類型的聯盟契約數量趨勢，代表性案例 (案例研究)，相關企業的一覽，契約的詳細資訊 (共2000件以上)等資訊彙整，為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 在藥物研發階段的化合物相關簽訂契約的理由

  • 簡介
  • 在藥物研發階段的聯盟所扮演的角色
    • 在藥物研發階段的引入授權
    • 在藥物研發階段的轉出授權
  • 在新藥發現、前臨床、臨床階段的交易的差異
  • 藥物研發階段簽訂聯盟契約的理由
    • 授權側 (授權人) 簽訂藥物研發階段契約的理由
    • 授權取得側 (被授權人) 簽訂藥物研發階段契約的理由
  • 在藥物研發階段的聯盟契約的未來性

第3章 在藥物研發階段的交易的策略與結構

  • 簡介
  • 在哪個階段各企業簽訂聯盟契約？
    • 跟製藥/生物科技企業的早期的聯盟
    • 跟製藥/生物科技企業的後期的聯盟
  • 在新藥發現、前臨床、臨床階段的聯盟:風險/成本比較
  • 在藥物研發階段的締結的支出額
  • 專門/複合契約的差異
  • 專門授權合約結構
    • 代表性案例
  • 多成分藥物研發階段合作夥伴契約
    • 在藥物研發階段的複合聯盟契約
    • 代表性案例

第4章 在藥物研發階段的聯盟的付款策略

  • 簡介
  • 在藥物研發階段的付款策略
  • 付款的選擇

第5章 在藥物研發階段的契約締結的趨勢

  • 簡介
  • 在藥物研發階段的契約締結:近幾年的趨勢
    • 契約的特徵
  • 在藥物研發階段的聯盟趨勢:各交易類型
  • 在藥物研發階段的聯盟趨勢:疾病的各類型
  • 聯盟趨勢:藥物研發階段的各技術種類
  • 在藥物研發階段的聯盟趨勢:最活躍的企業的情況 (2014年以後)

第6章 在藥物研發階段的聯盟契約的付款條件

  • 簡介
  • 在藥物研發階段的付款條件的指南
    • 預付款
    • 階段性付款
    • 特許權支付
  • 在藥物研發階段的付款條件:契約資料分析
    • 公共資料
    • 調查資料
  • 付款條件分析
    • 在藥物研發階段的契約總額
    • 在藥物研發階段的預付款
    • 在藥物研發階段的階段性付款
    • 在藥物研發階段的權利金費率

第7章 在藥物研發階段的主要契約

  • 簡介
  • 在藥物研發階段的主要契約:各金額

第8章 在藥物研發階段的最活躍的契約對方:前25名公司

  • 簡介
  • 在藥物研發階段的最活躍的契約對方:前25名公司

第9章 在藥物研發階段的聯盟契約的一覽

  • 簡介
  • 在藥物研發階段的聯盟契約動向 (2014年以後)

第10章 在藥物研發階段的契約締結:各臨床實驗階段趨勢

  • 簡介
  • 各藥物研發階段的交易趨勢

附錄

簡介目錄
Product Code: CP2056

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2016 including financial terms where available including over 3,900 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2016. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 25 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2016, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2016.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2016.

In addition, a comprehensive appendix of all discovery deals since 2016 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 provide the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2016
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 3,900 discovery stage deals
  • The leading discovery stage deals by value since 2016
  • Most active discovery stage dealmakers since 2016
  • The leading discovery stage partnering 2016

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive access to available deals and contract documents for over 3,900 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 3,900 discovery stage deals together with contract documents if available
  • Detailed access to actual discovery stage deals entered into by the leading 25 big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Identify leading discovery stage deals by value since 2016
  • Identify the most active discovery stage dealmakers since 2016
  • Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

  • 2.1. Introduction
  • 2.2. The role of discovery stage partnering
    • 2.2.1. In-licensing at discovery stage
    • 2.2.2. Out-licensing at discovery stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into discovery stage partnering deals
    • 2.4.1. Licensors reasons for entering discovery stage deals
    • 2.4.2. Licensees reasons for entering discovery stage deals
  • 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent discovery stage partnering agreements
    • 3.7.1.a. Example multicomponent early stage clauses
    • 3.7.1.a. Case study 11
    • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Discovery stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 13
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

  • 5.1. Introduction
  • 5.2. Discovery stage partnering over the years
    • 5.2.1. Attributes of discovery deals
  • 5.3. Discovery stage partnering by deal type
  • 5.4. Discovery stage partnering by disease type
  • 5.5. Partnering by discovery stage technology type
  • 5.6. Discovery stage partnering by most active company, 2016 to 2023

Chapter 6 - Payment terms for discovery stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for discovery stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Discovery stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Discovery stage headline values
    • 6.4.2. Discovery stage deal upfront payments
    • 6.4.3. Discovery stage deal milestone payments
    • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

  • 7.1. Introduction
  • 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Discovery stage deals with contracts 2016 to 2023

Chapter 10 - Discovery stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by discovery stage

Appendices

  • Appendix 1 - Discovery stage dealmaking by companies A-Z
  • Appendix 2 - Discovery stage dealmaking by industry sector
  • Appendix 3 - Discovery stage dealmaking by stage of development
  • Appendix 4 - Discovery stage dealmaking by therapy area
  • Appendix 5 - Discovery stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for discovery stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Discovery stage partnering frequency 2016- 2023
  • Figure 7: Discovery stage partnering by deal type since 2016
  • Figure 8: Discovery stage partnering by disease type since 2016
  • Figure 9: Discovery stage partnering by technology type since 2016
  • Figure 10: Top 25 most active discovery stage dealmakers, 2016 to 2023
  • Figure 11: Review of median upfront payments for discovery stage deals
  • Figure 12: Review of median milestone payments for discovery stage deals
  • Figure 13: Review of median royalty payments for discovery stage deals
  • Figure 14: Discovery stage deals with a headline value
  • Figure 15: Discovery stage deals with an upfront value
  • Figure 16: Discovery stage deals with a milestone value
  • Figure 17: Discovery stage deals with a royalty rate value
  • Figure 18: Top discovery stage deals by deal value since 2016
  • Figure 19: Most active discovery stage dealmakers 2016 to 2023